This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Inhibitors of coagulation factors

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Circulating inhibitors of blood coagulation may be found in:

  • hereditary coagulation disorders in response to replacement therapy - e.g. 5 to 10% of Haemophilia A patients have no circulating Factor VIII and produce antibodies against therapeutic Factor VIII
  • autoimmune disorders - e.g. rheumatoid arthritis
  • in women during the postpartum period
  • in elderly patients without underlying disease

The inhibitors are immunoglobulins, usually IgG or IgM, or rarely, IgA, and are targeted against specific coagulation factors. Inhibitors to Factor VIII:C are most common; but Factors V, IX and XI, and Factor VII:von Willebrand's Factor can also be affected. Severe bleeding may result.

Characteristically, the APTT is increased and is not corrected by 1:1 mixture of pooled and normal plasma.

Additionally:

  • PT is prolonged in Factor V inhibition
  • bleeding time is increased and ristocetin co-factor activity is abnormal in von Willebrands Factor inhibition

Refs: 1) Chesterman (1992). Haemostatic Failure. Med. Int. 97. 2) Schroeder (1991). Current: med. diag. and tr. Lange.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.